 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DermTech, Inc. ( DermTech or the Company ) (NASDAQ: DMTK). Such investors are advised...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of DermTech, Inc. - DMTK

Glancy Prongay &amp; Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of DermTech, Inc. (DermTech or the Company...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of DermTech, Inc. (DermTech or the Company) (NASDAQ: DMTK) investors concerning the Companys possible violations of federal...

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of DermTech, Inc. (DermTech or the Company) (NASDAQ: DMTK) on behalf of investors concerning the Companys possible violations of federal...

The Law Offices of Frank R. Cruz Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

Insider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 Shares

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

DermTech appoints Mark Aguillard chief commercial officer

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as...

DermTech Appoints Mark Aguillard as Chief Commercial Officer

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the grant to six new employees of restricted stock units representing the contingent right to receive up to an aggregate of 24,720 shares of...

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DermTech, Inc. (DMTK) Q2 2023 Earnings Call Transcript

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy with a Blues plan in Michigan. The favorable coverage policy, which is in addition to a contract that became...

DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in San Diego, CA.

Watchers	5,463
52-Wk Low	$1.51
52-Wk High	$6.43

Market Cap	$51.53M
Volume (M)	164,177.00
52-Wk High	$6.43
52-Wk Low	$1.51

DMTK DermTech Inc

About

Feed

News

Sentiment

Earnings

Fundamentals